イスラエルで最高のがん検診医師 - トップ19名の医師

オフェル・メリムスキー教授は、骨腫瘍・軟部腫瘍・中皮腫・肺癌・肝臓および肺への転移性病変を専門とする著名な腫瘍内科医です。スラスキー医療センター（イヒロフ、テルアビブ）の骨格・軟部腫瘍科の科長を務め、イスラエル臨床腫瘍医協会の会長を兼任しています。

主な専門領域と患者様へのメリット：

• 豊富な臨床経験と国際的な診療実績として、米国・フランス・イスラエルでの研修歴およびエルサレム大学での教育活動が挙げられ、高精度の先進的診断・治療法の提供が可能です。
• 腫瘍科的治療法には、肉腫・中皮腫・骨格および軟部腫瘍の治療のほか、放射線療法および小線源治療が含まれます。希少かつ難治性の腫瘍疾患に対しても、患者様は包括的な治療を受けることができます。
• 権威ある学術誌への多数の論文掲載実績として、New England Journal of Medicine（N Engl J Med）、Annals of Oncology、および欧州臨床腫瘍学会（European Society for Medical Oncology、ESMO）関連誌への発表があり、患者様が最新かつエビデンスに基づいた治療法を受けられることを保証しています。
• 国際学術団体への加盟として、Society of Oncologists and Radiotherapists Israel、ASCO、EMSOS、CTOSへの所属が、その高い専門性を証明するとともに、最新の治療プロトコルへのアクセスを可能にしています。
• オンライン診療を通じた遠隔診察・助言の提供が可能であり、世界どこからでも専門家による医療支援を受けることができます。

患者様はメリムスキー教授の深い腫瘍学的知識、個別化された治療計画の立案能力、そして細やかな対応を高く評価しており、治療の全過程を通じて安心感と信頼感が得られると好評です。

この医師は、消化管腫瘍の治療において30年以上の経験を持つ、著名な消化器専門医です。GIがんの予防、早期診断、および治療を専門としており、Sourasky Medical CenterのCancer Prevention Centerを率いています。

ヘブライ大学で一般医学の学位を取得し、テルアビブ大学で消化器学の専門を修了したこの医師は、NewYork-Presbyterian Centerで研究を行いました。この医師は300以上の論文を発表しており、American Association for Cancer ResearchやEuropean Society of Digestive Oncologyを含む、いくつかの著名な組織のメンバーです。

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Professor Dov Zippel is a general surgeon and surgical oncologist. He specializes in breast disease and melanoma. He leads the Meirav Breast Center at Sheba Medical Center. He also serves at the Ella Lemelbaum Institute for Immuno-Oncology. In 2025, Forbes Israel named him to its Best Doctors list.

Expertise: advanced care for benign and malignant breast tumors. Minimally invasive and breast-conserving surgery. Surgical treatment of melanoma and other skin cancers.

Accreditations: MD, Tel Aviv University. Residency in general surgery, Sheba Medical Center. Fellowship in surgical oncology, University of Calgary. Board-certified in general surgery and surgical oncology. Research includes intact breast lesion excision and perioperative BRAF inhibitors for stage III melanoma.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

アリ・ラファエル教授――テルアビブ・スラスキー医療センター（イキロフ、テルアビブ）トランスレーショナル腫瘍学部門長および臨床がん研究部門研究員。患者一人ひとりのニーズに寄り添う個別対応のアプローチが高く評価されています。

資格および患者への貢献：

• 腫瘍科デイホスピタルを統括し、国家ゲノム医療プロジェクトを主導。最先端の研究へのアクセスを提供しています。

• 主任副研究者および主任研究者として、腫瘍内mRNA投与やウイルス製剤を含むフェーズI〜IIIの多数の臨床試験に携わってきました。患者は革新的な治療法への参加機会を得られます。

• 米国および英国における国際的な臨床経験を有し、世界水準の治療基準と先進的なプロトコルの適用を保証しています。

• 国際学術団体の会員（ESMO、IASLC、ISLB、ISCORT、Israeli Medical Association）。最新の治療基準を活用し、国際的な研究に参画しています。

• 　ICH GCP R2、Israeli MOH Guidelinesをはじめ、インフォームドコンセント、副作用管理および患者安全に関する最新課程を含む国際臨床実践基準に基づき、定期的に専門知識の更新および研修を実施しています。

ラファエル教授は、精密な治療レジメンの選択、革新的手法の導入、そして細やかな患者対応により高い信頼を得ており、治療のすべての段階において患者が安心して療養に臨める環境を提供しています。

Dr. Michael Shapira is an experienced Bone Marrow Transplantation specialist, who speaks English and Hebrew, and graduated from the Hebrew university medical school in 1999.

• Specializes in Bone Marrow Transplantation
• Speaks English and Hebrew
• Graduated from Hebrew university medical school in 1999
• Specialized in internal medicine in Hadassah medical center
• Joined Bone Marrow Transplantation department in Hadassah as a senior physician

この医師は小児血液学および腫瘍学の分野での第一人者であり、特に小児の血液疾患および骨癌（肉腫）に特化しています。現在、この医師はテルアビブのSourasky Medical Centerの小児血液腫瘍科のディレクターを務め、Dana Children's Hospitalの上級小児科医でもあります。この医師は骨癌および軟部組織肉腫の治療を調整し、血液凝固障害を管理し、早産児の血液学を監督しています。この医師はイスラエル小児血液腫瘍学会（ISPHO）のメンバーです。

この医師はベングリオン大学を卒業し、Kaplan Medical Centerで小児医学を専門とし、Schneider Children's Medical Centerで小児血液学および腫瘍学をさらに専門としました。追加のトレーニングはイタリアのRizzoli Orthopaedic Instituteで骨および軟部組織の腫瘍学において完了しました。

教育

1994-1998 - ベラルーシ、グロドノ大学での医学勉強

専門化

2005-2010 - オンコロジー研修、テルアビブ医療センター、イチロブ

2000-2004 - 第10内科部門での研修、テルアビブ医療センター、イチロブ

1994-1995 - モジル医療センターでの研修、ベラルーシ

認められた専門知識

内科

腫瘍学

臨床経験

2015年から - 腫瘍入院のディレクター、テルアビブ医療センター、イチロブ

2005-2010 - 腫瘍学研修、テルアビブ医療センター、イチロブ

2000-2004 - 第10内科部門での研修、テルアビブ医療センター、イチロブ

2005年から - 腫瘍学における第1、第2、第3相臨床試験の主要研究者および副研究者

2000年1月 - イスラエルでの医師免許取得

1996-1998 - 一般開業医、モジル医療センター、ベラルーシ

1994-1995 - モジル医療センターでの研修、ベラルーシ

オーラ・ヒューバート博士はハダサ医療センターの医療腫瘍学者および放射線療法士で、英語とヘブライ語を話し、腫瘍学と放射線療法において33年の経験と資格を持っています。

• 医療腫瘍学 & 放射線療法の専門性
• 言語: 英語、ヘブライ語
• 卒業: 1990年（卒業から33年）
• 教育: 心理学、ヘブライ大学; 医学博士 ハダサ大学病院、イスラエル、エルサレム
• プロフェッショナルな経験: 胃腸癌センターの責任者; 上級医師、腫瘍学科、ハダサ大学病院; 研修医、腫瘍学科、ハダサ大学病院; インターン、ハダサ大学病院
• 認定: 理事会試験、腫瘍学 パート I; USMLE資格 パート I & II; 理事会試験、腫瘍学 & 放射線療法 パート II
• 会員: イスラエル臨床腫瘍学会; イスラエル医療協会; イスラエル癌協会; 胃腸癌委員会; 医療および社会サービス委員会

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Michael Lotem is the head of the Center for Melanoma and Cancer Immunotherapy at Hadassah Medical Center and is at the forefront of innovative research and patient treatment. Key takeaways about him include:

• Leads the Melanoma and Cancer Immunotherapy Center at Hadassah Hospital
• Studying the SLAM family of receptors in the anti-cancer immune response
• Involved with the treatment of melanoma patients with new immunotherapies
• Team includes clinicians and basic and translational researchers
• Immediate access to clinical data and patient-derived tissues

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.